Attenuated acute cardiac rejection in NOS2 -/- recipients correlates with reduced apoptosis

Circulation. 1999 Feb 16;99(6):836-42. doi: 10.1161/01.cir.99.6.836.

Abstract

Background: The mechanisms through which NOS2-mediated pathways regulate graft failure in acute cardiac rejection are ill defined. To determine whether apoptosis promoted by NOS2 may contribute, we used a heterotopic transplant model to study mouse cardiac allografts placed in recipients with targeted gene deletion of NOS2.

Methods and results: Using 5 different indexes of apoptosis, we showed that mouse cardiac allografts placed in NOS2 -/- recipients (n=7) had reduced apoptotic activity compared with those in NOS2 +/+ controls (n=8). There were significantly fewer TUNEL-positive nuclei per high-powered field (P<0.01), less DNA fragmentation (antinucleosome ELISA; P<0.05), lower corrected transcript levels for caspase-1 and -3 (32P reverse transcriptase-polymerase chain reaction; P<0.01), and reduced caspase-3 activity (cleavage of DEVD-pNA [P<0.001] and poly [ADP-ribose] polymerase) in grafts from NOS2 -/- recipients. This concordant reduction in apoptotic indexes paralleled the improved histological outcome of grafts transplanted into NOS2 -/- recipients (assessed as rejection scores; P=0.012). To identify pathways controlled by NOS2, we compared intragraft transcript levels of potential triggers and regulators. Whereas Fas ligand/Fas and tumor necrosis factor (TNF)-alpha/TNF receptor-1 levels were not altered by NOS2 deficiency, transcript levels for p53 were significantly lower in grafts from NOS2 -/- recipients, coinciding with a significant increase in the antiapoptotic Bcl-2/Bax balance and decrease in Bcl-Xl levels.

Conclusions: Using NOS2 knockout mice, we demonstrated that NOS2-mediated pathways can promote acute rejection, at least in part, by inducing apoptotic cell death. When NOS2 is present, p53 might control NOS2-mediated apoptosis by stimulating Bax and repressing Bcl-2 and Bcl-Xl expression, which may activate the cell death program in the rejecting heart.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Apoptosis / immunology*
  • Caspase 3
  • Caspases / metabolism
  • Coumarins / pharmacology
  • Cysteine Proteinase Inhibitors / pharmacology
  • DNA Primers
  • Enzyme Activation / drug effects
  • Gene Expression Regulation, Enzymologic
  • Graft Rejection / enzymology*
  • Heart Transplantation*
  • In Situ Nick-End Labeling
  • Mice
  • Mice, Inbred CBA
  • Mice, Knockout
  • Muscle Fibers, Skeletal / cytology
  • Muscle Fibers, Skeletal / enzymology
  • Muscle Fibers, Skeletal / transplantation*
  • Myocardium / chemistry
  • Myocardium / cytology
  • Myocardium / enzymology
  • Nitrates / analysis
  • Nitric Oxide Synthase / genetics*
  • Nitric Oxide Synthase / metabolism
  • Nitric Oxide Synthase Type II
  • Oligopeptides / pharmacology
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases
  • Proteins / metabolism
  • RNA, Messenger / analysis
  • Transplantation Immunology
  • Transplantation, Homologous
  • Tumor Suppressor Protein p53 / genetics
  • Tyrosine / analysis

Substances

  • Ac-aspartyl-glutamyl-valyl-aspartyl-aminomethylcoumarin
  • Coumarins
  • Cysteine Proteinase Inhibitors
  • DNA Primers
  • Nitrates
  • Oligopeptides
  • Proteins
  • RNA, Messenger
  • Tumor Suppressor Protein p53
  • peroxynitric acid
  • Tyrosine
  • Nitric Oxide Synthase
  • Nitric Oxide Synthase Type II
  • Nos2 protein, mouse
  • Parp1 protein, mouse
  • Poly (ADP-Ribose) Polymerase-1
  • Poly(ADP-ribose) Polymerases
  • Casp3 protein, mouse
  • Caspase 3
  • Caspases